- LY 303511
-
- $562.00 / 50mg
-
2026-05-11
- CAS:154447-38-8
- Min. Order:
- Purity: 99.91%
- Supply Ability: 10g
- LY 303511
-
- $2.00 / 100kg
-
2026-04-17
- CAS:154447-38-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
- LY 303511
-
- $1.00 / 1KG
-
2019-12-20
- CAS:154447-38-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kgs
|
| | LY 303511 Basic information |
| Product Name: | LY 303511 | | Synonyms: | LY 303511; LY303511;2-(1-Piperazinyl)-8-phenyl-4H-1-benzopyran-4-one;8-Phenyl-2-(1-piperazinyl)-4H-1-benzopyran-4-one;8-Phenyl-2-(1-piperazinyl)-4H-1-benzopyran-4-one LY303511;LY303511, >=98%;4H-1-Benzopyran-4-one, 8-phenyl-2-(1-piperazinyl)-;LY-303511(Nv-128);8-phenyl-2-(piperazin-1-yl)-4H-chromen-4-one | | CAS: | 154447-38-8 | | MF: | C19H18N2O2 | | MW: | 306.36 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 154447-38-8.mol |  |
| | LY 303511 Chemical Properties |
| Boiling point | 496.1±45.0 °C(Predicted) | | density | 1.237±0.06 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | Soluble to 100 mM in 1eq. HCl and to 100 mM in DMSO | | pka | 9.20±0.10(Predicted) | | form | Amber solid | | color | amber | | InChI | 1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2 | | InChIKey | NGAGMBNBKCDCDJ-UHFFFAOYSA-N |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| | LY 303511 Usage And Synthesis |
| Uses | LY 303511 is an inactive analog of the phosphoinositide 3-kinase inhibitor LY294002. | | Definition | ChEBI: 8-phenyl-2-(1-piperazinyl)-1-benzopyran-4-one is a N-arylpiperazine. | | Biological Activity | Negative control compound with respect to LY 294004 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-onehydrochloride ) PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (K v ) channels (IC 50 = 64.6 μ M) and inhibits IL-1 β -stimulated NF- κ B activation, attenuating MCP-1 expression. Anti-proliferative. | | in vivo | Intraperitoneal administration of vehicle or LY303511 (10 mg/kg/day) is performed when tumors reach a volume of ~150 mm3, at which time 35 mice have developed a tumor. After 21 days, >15% of the mice require euthanasia because of excessive tumor growth, and these data are censored due to unreliable estimates of average tumor volume. The administration of LY303511, 10 mg/kg/day, is sufficient to inhibit PC-3 tumor growth in vivo[4]. |
| | LY 303511 Preparation Products And Raw materials |
|